52 Week Range
As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Chr. Hansen And UPL Announce A Long-Term Collaboration
Chr. Hansen Q4 EBIT Ex-Items At EUR 84.2 Mln
Chr.Hansen Holding Interim Report Q3 2020/21
Chr Hansen Holding A/S is a Denmark-based bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The Company’s business is divided into three divisions, namely Food Cultures & Enzymes, Health & Nutrition and Natural Colors. The Food Cultures & Enzymes division develops and produces cultures, enzymes and probiotics for the food industry in general and the dairy industry in particular. The Health & Nutrition division develops, produces and sells products for the dietary supplement, over-the-counter pharmaceutical, infant formula and animal feed industries. The Natural Colors division develops and supplies natural color solutions to the food and beverage industry, in particular the beverage, confectionery, ice cream, dairy, fruit preparation and prepared food segments. The Company operates in Europe, North and South America, as well as Asia Pacific, Middle East and Africa.
Boege Alle 10-12
Independent Chairman of the Board
President, Chief Executive Officer, Member of the Executive Board
Independent Vice Chairman of the Board
Lise Skaarup Mortensen
Chief Financial Officer, Executive Vice President, Member of the Executive Board
Executive Vice President, Chief Scientific Officer, Research & Development, Member of the Executive Board
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Danish ingredients maker Chr Hansen Holding A/S said on Saturday it would sell its food colouring business to Swedish private equity firm EQT for 800 million euros ($930.40 million).
* THE FULL-YEAR OUTLOOK IS MAINTAINED, BUT ASSUMES NO SIGNIFICANT SUPPLY DISRUPTION FROM COVID-19.
* REG-CHR. HANSEN AND LONZA’S NEWLY BRANDED JOINT VENTURE, BACTHERA, RECEIVES ANTI-TRUST APPROVALS TO START CONTRACT MANUFACTURING OF LIVE BIOTHERAPEUTIC PRODUCTS
* ANNOUNCED ON TUESDAY WILL ESTABLISH 50/50 JOINT VENTURE WITH LONZA AG
* CEO Mauricio Graber on Jan. 17 purchased a total of 2,500 Chr. Hansen's shares at DKK 588.20 per share
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.